Table 3.
Author and Date | Type of Study | Probiotic Type | Dosage and Time of Exposure | Main Findings | Possible Mechanisms | Quality of Life and Symptoms, and so on |
---|---|---|---|---|---|---|
Xu et al 201659 | Randomized, double-blind, placebo-controlled crossover study with 15 adults | Clostridium butyricum (Cb) | Unclear dose for 7 months | IgE, B cells↓ Th2 cells↓ Treg, IL10↑ |
Inhibition of Th2 immune response | Add-on probiotic therapy enhanced SCIT in patients with AR |
Jerzynska et al 201661 | Prospective and double-blind, randomized, placebo-controlled with 100 children | L. rhamnosus GG | 1000 IU daily for 5 months | IL1, IL6↓ IL10, IL12, TGFβ↑ Th1 cells↑ CD4+CD25+Foxp3+↑ |
Enhance immune response | Add-on probiotic therapy enhanced SLIT in children with AR |
Del et al 201752 | Randomized, double-blind, placebo-controlled study with 40 children | B. longum BB536, B. infantis M-63, B. breve M-16V | B. longum BB536 (3x109 CFU), B. infantis M-63 (1x109 CFU), and B. breve M-16 V (1x109 CFU) daily for 8 weeks | ## | ## | Improved AR symptoms and QoL |
Berings et al 201755 | Randomized, double-blind, placebo-controlled crossover study with 20 adults | B. subtilis, B. amyloliquefaciens, B. pumilus strains | Bedding for house Purotex® covers 8 weeks | ## | ## | Improved AR symptoms and QoL |
Qiao et al 201757 | Double-blind, placebo-controlled with 40 adults | Clostridium butyricum duplex viable | 3 capsules/time Twice a day for 6 weeks | IL10, TGFβ↑ | Inhibition of Th2 immune response | Improved AR symptoms and VAS, RQLQ |
Juan et al 201766 | Randomized, double-blind, placebo-controlled study with 40 BALB/c mice | Clostridium butyricum CGMCC0313-1 | 1×108 CFU daily for 2 weeks | IL4, IL5, IL13, IL17↓ IgE/G1↓ IL10↑ CD4+CD25+Foxp3+↑ | Th1/Th2 Cytokine balance | Alleviates inflammation |
Harata et al 2017121 | Double-blind, randomized, placebo-controlled study with 25 pollinosis patients | Lactobacillus rhamnosus GG Lactobacillus gasseri TMC0356 | 110g fermented milk daily for 10 weeks | Restore intestinal microbiota balance | Regulating blood lipids | Alleviates inflammation |
Choi et al 201865 | Randomized, double-blind, placebo-controlled study with 35 BALB/c mice | Lactobacillus plantarum CJLP133 and CJLP243 | 1×1010 CFU daily for 17 days | IL4, IL5, IL13↓ IgE, IgG1↓ IgG2a, IFNγ↑ Th1 cells↑ |
Th1/Th2 Cytokine balance | Reduce inflammation and symptoms |
Ren et al 201872 | Randomized, double-blind, placebo-controlled study with # #BALB/c mice | Bifidobacterium breve | Unclear dose for 4 weeks | IL4, IL10↓ IgE↓ CD4+CD25+Tregs↑ |
Inhibition of Th2 immune response | Improved AR symptoms |
Ahmed et al 201950 | Randomized controlled study with 212 children | L. paracasei LP33 | 2x109 CFU daily for 6 weeks | IgE↓ | Promote Th1 immunity and inhibit Th2 response | As effective as cetirizine for perennial AR |
Jalali et al 201958 | Randomized, double-blind, placebo-controlled crossover study with 152 adults | L. acidophilus, L. casei, L. delbrueckii subsp. L. bulgaricus, and L. rhamnosus | 11.5×1010 CFU daily for 8 weeks | ## | ## | Add-on probiotic therapy was more effective than budesonide |
Meng et al 201962 | Randomized, placebo-controlled study with 60 patients | Broncho-vaxom (BV) | 7mg daily for 10 days, resting 20 days, 3 courses | IL4, IL13↓ eosinophils↓ IFNγ↑ |
Th1/Th2 Cytokine balance | Improved TNSS and INSS score |
Makino et al 201968 | Randomized, double-blind, placebo-controlled study with ## Ovalbumin (OVA)-specific TCR-transgenic DO11.10 mice | L. helveticus SBT2171 | Unclear dose for 6 weeks | IL4, IL13↓ Leukocyte infiltration↓ IL10, IFNγ↑ Th1 cells↑ |
Th1/Th2 Cytokine balance | Alleviates allergic symptoms |
Schaefer et al 2019122 | Randomized, double-blind, placebo-controlled crossover study with 120 patients | Enterococcus faecalis | 30 drops each time, 3 times daily for 8 weeks | Restore intestinal microbiota balance | Regulate immune response | Improved AR symptoms |
Kim et al 2019123 | Randomized, double-blind, placebo-controlled crossover study with 48 BALB/c mice | Bifidobacterium longum IM55 and Lactobacillus plantarum IM76 | 2×109 CFU daily for 30 days | IL4, IL5↓ Th2 cells, Mast cells ↓ eosinophils, basophils↓ Bacteroides↓ Proteobacteria↑ Actinomycetes↑ |
Restoring Th2/Treg imbalance and gut microbiota disturbance | Improved AR symptoms |
Yamashita et al 202051 | Randomized, double-blind, placebo-controlled study with 200 adults | L. helveticus SBT2171 | 10g daily for 12 weeks | IgE↓ eosinophils↓ |
Th1/Th2 Cytokine balance or Inhibition of Th2 immune response | Improved AR symptoms |
Kang et al 202053 | Multi-center, double-blind, randomized, placebo-controlled with 97 adults | B. longum IM55, L. plantarum IM76 | 1×1010 CFU daily for 4 weeks | IL4, IL5, IL13↓ PDG2↓ Cysteine LTs↓ IgE↓ Mast cells↓ B cells↓ eosinophils↓ Th2 cells↓ Treg↑ IL10↑ |
Th1/Th2 Cytokine balance | Improved TNSS and RCAT score |
Anania et al 202154 | Prospective and double-blind, randomized, placebo-controlled with 250 children | Lactis BB12, Enterococcus faecium L3 | 4×1010 CFU daily for 3 months | ## | ## | Improved NSS score |
Bae et al 202167 | Randomized, double-blind, placebo-controlled crossover study with # #BALB/c mice | Fermented by probiotic bacteria (FRG) | Unclear dose for more than 2 weeks | IL4, eosinophils↓ basophils, IgE↓ |
Inhibition of Th2 immune response | Alleviates inflammation |
Hu et al 2021124 | Randomized, double-blind, placebo-controlled crossover study with 130 children | Lactobacillus reuteri GL-104, Lactobacillus paracasei GL-156, Lactobacillus rhamnosus MP-108 | 500mg each time, 3 times daily for 12 weeks | Restore intestinal microbiota balance | Restore intestinal barrier function | Alleviates inflammation |
Yang et al 202271 | Randomized, double-blind, placebo-controlled crossover study with # #BALB/c mice | Lactiplantibacillus plantarum NR16 | Unclear time and dose | IL12, IFNγ↑ | Induce Th1 immune response and balance Th2/Th1 ratio | Improved AR symptoms |
Abbreviations: AR, allergic rhinitis; QoL, quality of life; RCAT, rhinitis control assessment test; SCIT, subcutaneous immunotherapy; SLIT, sublingual immunotherapy; NSS, nasal symptom score; INSS, individual nasal symptom score; TNSS, total nasal symptom score; VAS, visual analogue score; RQLQ, rhinoconjunctivitis quality of life scale; ##, not mentioned or not applicable.